Mirtazapin Amarox (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapin Amarox, is a noradrenergic and specific serotonergic antidepressant (NaSSA) presented as an oral tablet for systemic use. It is indicated for the management of major depressive disorder in adult patients, helping to improve mood and sleep patterns.

GNH USA supplies Mirtazapin Amarox as a licensed, Good Distribution Practice‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics across global markets while adhering to EU regulatory standards and ensuring product quality and traceability.

Mirtazapine is a NaSSA antidepressant used primarily in the treatment of mood disorders.

- Major depressive disorder: reduces depressive symptoms and enhances overall mood. - Depressive episodes in bipolar disorder (adjunct): supports mood stabilization when combined with mood stabilisers. - Anxiety associated with depression: may lessen anxiety symptoms that coexist with depressive illness.

Mirtazapine may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness - Peripheral edema

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Seizures - Severe hypersensitivity reactions such as Stevens‑Johnson syndrome

Before prescribing Mirtazapine, clinicians should consider several safety aspects.

- Pregnancy: safety category is unknown; weigh potential benefits against risks. - Breastfeeding: drug passes into milk; assess infant risk. - Elderly patients: monitor for increased sedation and falls. - Hepatic impairment: dose adjustment may be required. - Concomitant CNS depressants: avoid additive sedation. - Store at ambient temperature: keep in original container, protect from moisture and light.

Mirtazapine can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of serotonin syndrome. - Potent CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase mirtazapine levels.

Moderate Interactions (Monitor Closely): - Other serotonergic agents (e.g., SSRIs, SNRIs): monitor for serotonin excess. - CNS depressants (e.g., benzodiazepines, alcohol): watch for enhanced sedation. - Anticholinergic drugs: may worsen dry mouth and constipation.